Parmal

Quick links to important sections

Parmal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parmal

Quick Facts

Property Description
Active Ingredient Pyrilamine (Mepyramine)
Form Tablet, Capsule, Oral Liquid, Topical Cream
Pharmacological Class First-generation H1-receptor Antagonist
General Purpose Relieves allergic physical irritations and provides mild sedation
Origin Synthetic (Ethanolamine derivative)

What is Parmal and its Active Composition?

Parmal is the trade name for a synthetic medicinal entity whose active compound is Pyrilamine maleate, functioning as a systemic agent recognized for its anti-allergic properties. The active ingredient, Pyrilamine (also known as Mepyramine), is structurally classified as an Ethanolamine derivative, affirming its synthetic origin. This substance, typically administered as the maleate salt, is the core component responsible for the drug's activity throughout the body. Parmal is often marketed as an Over-the-Counter (OTC) product and is encountered both as a Combination product alongside other active agents and as a single ingredient medicine.

What Type of Antihistamine is Pyrilamine?

Pyrilamine is formally classified as a First-generation antihistamine and a non-selective H1-receptor antagonist, distinguishing its mechanism of action within its pharmacological class. This designation means the compound readily permeates the central nervous system, a characteristic clinically recognized for this class of agents. First-generation antihistamines are distinct from newer variants due to their pronounced ability to cross the blood-brain barrier. The medicine is supplied in various common dosage forms, including an oral tablet or capsule, an oral liquid, and a topical cream, permitting its use via the Oral or Topical routes of administration.

What is the General Purpose of Parmal?

The general purpose of Parmal is to counteract the effects of histamine by blocking the H1 receptor, thereby helping to lessen the physical irritations associated with allergic reactions, such as those experienced during seasonal discomfort. By means of this Histamine H1 receptor blockade, the compound works to suppress manifestations such as itching, swelling, and redness. Characteristic of its class, the compound also possesses a noticeable sedative effect, which arises from its activity within the central nervous system, offering a secondary calming property alongside its primary anti-allergic function.

Regulatory References

  1. European Medicines Agency

What side effects are possible with Parmal?

Possible Side Effects and Safety Information

The safety profile for Pyrilamine maleate (Parmal), as documented in official regulatory sources, is primarily characterized by effects linked to its classification as a first-generation antihistamine. These effects are generally grouped into Central Nervous System (CNS) depression and anticholinergic actions.

Officially Classified Adverse Reactions

Adverse reactions are classified by frequency and affected body system:

Classification/System Officially Documented Effects
Common Drowsiness, Dizziness, Dry mouth, Dry throat, Dry nose, Constipation
Nervous System Blurred vision, Headache, Confusion, and rarely, Seizures
Urinary/Renal Difficulty urinating, Urinary retention

Serious Adverse Reactions and Safety Constraints

Official labeling contains specific warnings regarding less frequent but more serious adverse reactions and safety limitations:

Serious Adverse Reactions: Rare, severe events documented include Severe Allergic Reactions (such as blistering, facial swelling, hives, or shock) and the potential for Seizures.

Population-Specific Considerations: The drug's effects vary in certain groups. Older adults may exhibit increased sensitivity to the CNS and anticholinergic effects, leading to a higher potential for Drowsiness, Dizziness, Confusion, and problems with urination. Children may experience a paradoxical reaction, such as increased Excitability, Nervousness, or Agitation, instead of sedation, which requires specific safety notes.

Interaction Constraint: The risk of increased Drowsiness is explicitly highlighted when Pyrilamine maleate is used alongside substances that depress the CNS, such as alcohol, sedatives, or tranquilizers.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Parmal (which refers to paracetamol or acetaminophen) is a medical emergency that poses a risk of severe, potentially fatal hepatotoxicity (liver damage). This risk is present following a single large ingestion or from a staggered overdose (taking too much over a period of time).

When to Seek Immediate Medical Help

Immediate medical assessment and treatment are required for any suspected overdose. It is critical to contact emergency medical services or a poison control center immediately after ingestion, even if the person appears well or has no symptoms.

Documented Overdose Presentation

Initial signs of an overdose are often non-specific and may be delayed for 24 hours or more. Initial manifestations may include nausea, vomiting, or abdominal pain. As the poisoning progresses, signs of severe liver injury may develop, including abnormal liver function tests, jaundice, encephalopathy (confusion), and issues with blood clotting.

Emergency Response

Prompt treatment with the antidote, N-acetylcysteine, is essential to mitigate the risk of severe liver damage. The efficacy of this life-saving treatment is significantly reduced if administration is delayed beyond the first several hours following ingestion. Regulatory documents emphasize that immediate action is necessary to ensure the antidote is administered within the critical therapeutic time window.

Therapeutic Uses of Parmal

Parmal is used to provide supportive relief across key domains of acute discomfort and systemic distress. This class of medication is commonly applied when symptoms become noticeable and create temporary interference with daily stability, offering short-term symptomatic assistance.

Acute Relief for Heightened Physical Discomfort

Parmal is used in situations involving certain distressing symptoms of physical discomfort, such as headaches, backaches, muscle pain, or menstrual cramps, that may appear suddenly or fluctuate. It is used for managing symptom clusters that create noticeable physiological strain, and is applied when short-term symptomatic assistance is needed. The medication is commonly used to help with symptoms of tension headaches, muscular aches, and fever associated with acute episodes of systemic discomfort.

“It contributes to easing the overall symptom load, offering symptomatic relief that helps patients cope more steadily with difficult episodes.”

Supportive Management for Systemic Symptoms

This medication is relevant in contexts marked by increased discomfort or tension, particularly for managing symptoms related to systemic manifestations. It is often used during phases when symptoms become more noticeable, helping to support general well-being and contributing to improved comfort during periods of heightened symptoms.


Symptom Focus: Episodic Discomfort Management Parmal is commonly used across conditions presenting with acute episodes or fluctuating manifestations, and may assist with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. U.S. National Library of Medicine MedlinePlus overview

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

Populations for whom use is contraindicated: Use of Parmal (Pyrilamine) is strictly prohibited by regulatory labeling in individuals with a known hypersensitivity to the active compound or related antihistamines. Absolute non-eligibility also applies to patients taking Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Due to its classification as a first-generation antihistamine, the medicine is contraindicated for those with narrow-angle glaucoma, an acute asthma attack, or symptoms related to symptomatic prostatic hypertrophy or bladder neck obstruction, as defined by regulatory documents.

Age-related eligibility and conditional use: The drug is generally contraindicated in infants and very young children. Its use is typically not established for pediatric populations below specific age thresholds (which vary by regional label and formulation). Older adults require use with caution due to increased sensitivity to potential effects.

Condition-specific limitations: Use is restricted or requires caution in populations with compromised drug processing or excretion, specifically individuals with significant hepatic (liver) impairment and severe renal (kidney) impairment. Caution is also warranted for patients with pre-existing cardiovascular disease or hypertension.

Pregnancy and lactation status: The official status for use during pregnancy is restricted, generally permitted only when the potential benefit to the patient justifies the potential risk. Use is not recommended for nursing mothers, as the substance passes into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several categories of substances that interact with Parmal, focusing primarily on pharmacodynamic potentiation and metabolic pathways.

Contraindicated and Time-Separated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including phenelzine and isocarboxazid, is formally classified as a contraindicated combination due to the risk of severe interaction. The regulatory label mandates a mandatory two-week washout period; MAOIs must not be used for 14 days prior to starting Pyrilamine treatment. Combination with Thalidomide is also officially prohibited due to the severe increase in sedation risk.

Pharmacodynamic and Substance Interactions

Co-administration with other Central Nervous System (CNS) Depressants (e.g., opioid relievers, sleep medications) and substances like Alcohol or Marijuana (Cannabis) results in officially documented additive effects, increasing the severity of sedation and drowsiness. The combination with other agents possessing Anticholinergic Effects also yields additive outcomes, such as increased risk of urinary retention.

Metabolic and Clearance Considerations

Pyrilamine may influence the CYP450 enzyme system, and official caution is advised when co-administering drugs that are substrates, inhibitors, or inducers of this system. The regulatory profile notes that patients with hepatic or renal impairment face a heightened risk of adverse effects due to potential drug and metabolite accumulation from reduced clearance, a population-specific interaction consideration.

Mechanism of Action

Parmal is a monoclonal antibody designed to specifically target RANKL (Receptor Activator of Nuclear Factor kappaB Ligand).

Parmal binds to RANKL with high affinity, functionally neutralizing this ligand. By binding to soluble and cell-surface RANKL, Parmal prevents its necessary interaction with the RANK receptor expressed on the surface of osteoclast precursors and mature osteoclasts.

This receptor-ligand inhibition prevents the downstream intracellular signaling cascade—including activation of NF-kappaB and AP-1—that is essential for osteoclast differentiation, function, and survival. Consequently, the drug mediates a rapid and significant decrease in the formation and activity of osteoclasts, the cells responsible for bone resorption. The resultant physiological effect is a shift in the bone remodeling unit activity, leading to a modulated balance of osteoblast (formation) and osteoclast (resorption) activity toward the anabolic phase of bone turnover. The drug's action is confined to this molecular pathway.

Dosage and Administration Information

How to Use Parmal: Official Administration Guidelines

The usage of Parmal, which contains Pyrilamine maleate, is defined by specific administration routes and dosage schedules. The medicine is available in forms designated for both oral administration (e.g., tablets, caplets, and liquid suspensions) for systemic relief and topical/cutaneous application (e.g., cream or spray) for local effect.

Standard Dosing Regimens

The frequency of use depends on the formulation, distinguishing between fixed schedules and as-needed use. Standard-release oral caplets are typically used on an as-needed (p.r.n.) basis, with repetition allowed every 6 hours. However, extended-release oral suspensions are generally administered on a fixed every 12 hours schedule. For the topical cream, application is typically recommended two or three times each day.

Dosing Limits and Conditions

Limits are defined for both quantity and duration. For certain oral combination products, the total intake must not exceed 6 caplets per day. The topical cream application is strictly limited to a maximum course duration of up to three days. Oral caplets are explicitly instructed to be taken with water. The topical form is constrained to external use only and must not be applied to large or broken areas of skin.

Population-Specific Guidance

While adults and children 12 years and older follow the general adult regimen, children under 12 years are advised to only use the medication after consulting a healthcare professional. Specific, lower pediatric dosages are detailed for children aged 6 to under 12 years for certain liquid formulations, as use patterns are dependent on the patient's age and the specific product form.

The resulting procedural structure dictates a standardized approach, where administration is governed by the determined route, the fixed or p.r.n. frequency, and strict limits on the maximum daily quantity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Parmal

Evidence for Relief of Allergic Symptoms

Pyrilamine (Parmal) was studied to evaluate the observable patterns of symptoms linked to allergic reactions, which are conditions characterized by fluctuating or episodic manifestations. The research exploring this use largely involves short-term Randomized Controlled Trials (RCTs) and historical clinical studies. These trials research examined how symptoms such as sneezing, runny nose, and eye irritation change over defined time intervals. The populations was evaluated in generally included adults and older adolescents, sometimes comparing the compound against a placebo or another active comparator.

Findings describe patterns observed in the studies; data observed are aligned with the characteristics of the compound's class. These studies report how symptoms evolved in the observed populations over brief periods, focusing on patient-reported outcomes. Research provides insight into short-term changes observed during episodes of allergic distress.

Evidence Structure for Acute Discomfort Management

Research on Pyrilamine for outcomes related to physical discomfort, often involved its use as a component in combination products alongside analgesic agents. These RCTs was used in research exploring how symptoms change over time, focusing on outcomes describing episodic or acute changes during conditions involving periods of heightened symptoms, such as headache or muscle ache.

Research on the Secondary Sedative Property

The compound was evaluated in dedicated pharmacodynamic studies and historical clinical observations related to its secondary sedative property. This research examined outcomes reflecting daily functioning or activity level and measured objective parameters such as time to sleep onset in healthy adult volunteers.

These studies data show patterns related to the presence of drowsiness, which was observed in some studies involving members of this chemical class. The research highlights changes measured during the study period following single doses or short-term use.

The Landscape of Evidence Gaps and Uncertainty

The overall evidence quality varies across studies. A significant limitation is that the primary support for its allergy relief and sedative properties is drawn from the entire class of first-generation antihistamines, meaning comparative evidence is lacking for Pyrilamine against many newer treatments. The evidence base also shows mixed findings regarding its specific contribution to acute pain relief when used in combination formulas. Ultimately, evidence highlights what is known — and what is still uncertain, confirming that results apply only to the populations studied and the specific conditions under which the research was conducted.

Key Studies & References Antihistamines (Oral) - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Parmal (FAQ)

Q: What is the main reason doctors prescribe Parmal?

According to official product information, the active ingredient Pyrilamine maleate is prescribed to provide temporary relief of symptoms associated with allergic conditions such as allergic rhinitis, allergies, and common cold symptoms like a runny nose or sneezing. In multi-ingredient forms, the medicine may also be used for temporary relief of symptoms like headache or menstrual pain.


Q: Is Parmal the same type of medicine as [similar common drug name]?

Regulatory agencies classify Pyrilamine maleate, the ingredient in Parmal, as an antihistamine (specifically an H1 antagonist). When it is part of multi-ingredient products, it may also be categorized under classes like upper respiratory combinations or analgesic combinations, depending on what the other ingredients are.


Q: Is Parmal a painkiller or an anti-inflammatory medicine?

The active ingredient Pyrilamine maleate is classified primarily as an antihistamine. However, it is often manufactured in combination products where it is paired with an ingredient classified as a pain reliever (analgesic). The regulatory classification as an antihistamine distinguishes the primary action from that of a dedicated painkiller.


Q: How long does one dose of Parmal typically last in the body?

Official dosing instructions provide insight into the duration of the effect. For standard-release oral products, the instructions typically advise repeating the dose every 6 hours as needed. This indicates the frequency at which the dose is permitted to be repeated according to label instructions.


Q: Do I need to take Parmal every day, or only when I feel symptoms?

The required schedule depends on the specific product formulation. Instructions for standard-release products often state to take the medication 'as needed' (p.r.n.) for symptom relief. However, fixed schedules, such as every 12 hours, may be specified for extended-release versions or certain combination products.


Q: Is it normal to feel a little dizzy when first starting Parmal?

Official regulatory documents list dizziness as a common side effect associated with the use of Pyrilamine maleate. While the product information does not specify if this effect is more intense during the initial period of use, the regulatory documents confirm dizziness is a commonly reported adverse reaction associated with the drug class.


Q: Can I take Parmal if I am already taking blood pressure medication?

Official labeling advises patients to 'Ask a doctor before use' if they have certain pre-existing conditions or are currently taking other medicines. This guidance emphasizes the need for a healthcare professional to evaluate potential individual risks and interactions with other medicines, including blood pressure medication.


Q: Does Parmal interact with supplements like vitamins or herbal remedies?

Regulatory labeling advises patients to 'Ask a doctor or pharmacist' before using the medication if they are also taking other prescription or nonprescription medicines. This is part of the overall regulatory guidance that stresses caution regarding all other substances being used.


Q: Can people with liver conditions use Parmal?

Official drug labels state that patients should 'Ask a doctor before use' if they have liver disease. This warning is present because regulatory documents note that patients with hepatic impairment face a heightened risk of adverse effects due to potential accumulation of the drug.


Q: What are the requirements for being eligible to take Parmal?

Eligibility is defined by whether the patient’s symptoms align with the product’s labeled uses (e.g., temporary relief of cold symptoms). It also depends on the absence of known contraindications, such as a prior allergic reaction to the ingredients, as well as adherence to any stated age limits.


Q: Is Parmal known to cause any skin reactions or rashes?

Official warnings in the drug labels note that signs of a serious adverse event may include skin reddening, blisters, or rash. The labeling emphasizes that if these signs appear, consultation with a healthcare professional is advised.


Q: Are there certain foods or drinks I should avoid while on Parmal?

Regulatory documents explicitly warn about the use of alcoholic drinks while taking the medication, as this can increase the known side effect of drowsiness. Beyond alcohol, specific food restrictions are typically not listed.


Q: Is Parmal considered a 'new' drug or has it been used for a long time?

Pyrilamine maleate is a compound that has been in use and indexed in medical databases for a considerable time, with some sources tracing its introduction as far back as the 1970s. Its classification is that of a first-generation antihistamine.


Q: Can Parmal be used during pregnancy or while breastfeeding?

Official labeling states, 'If pregnant or breast-feeding, ask a health professional before use.' Because this information must be assessed on an individual basis, consultation with a healthcare professional is noted in the label as required before use.


Q: Is Parmal a controlled substance?

Pyrilamine maleate, the active ingredient in Parmal, is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) or typically by other governmental scheduling bodies.


Q: Does Parmal affect blood sugar levels?

Labels for certain liquid or combination products may advise caution if a patient has diabetes. The warning is generally tied to other components in the product, and regulatory documents do not describe the primary active ingredient as directly affecting blood sugar.


Q: Why is Parmal sometimes combined with other ingredients in a single pill?

Official product information indicates that Pyrilamine maleate is combined with other active ingredients, such as pain relievers or diuretics, to create a single product. This is done to provide temporary relief for multiple, co-occurring symptoms, such as those associated with colds or menstrual periods.


Q: Is Parmal used for more than one main health condition?

Regulatory documents confirm that Pyrilamine maleate is used for the temporary relief of symptoms associated with multiple conditions, primarily allergic rhinitis and general allergies. It is also an ingredient in combination products indicated for temporary relief of symptoms related to menstrual periods.


Q: Does taking Parmal cause changes in mood or anxiety?

Adverse reaction lists in regulatory documents include effects related to the central nervous system, such as confusion, excitability, nervousness, and agitation. These documented effects are part of the nervous system and behavioral changes listed in the official safety profile.


Q: Is Parmal a prescription-only medicine?

Pyrilamine maleate is commonly found as an active ingredient in Over-the-Counter (OTC) products in the US and other regions. This classification means the product is intended to be available for purchase without a prescription.


Q: How is Parmal classified by government health agencies?

Governmental health agencies classify Pyrilamine maleate as a first-generation antihistamine (H1 antagonist). This classification is based on its mechanism of action and its recognized mild sedative properties.


Q: Are there any specific safety warnings for people with heart issues taking Parmal?

Official labeling advises patients to 'Ask a doctor before use' if they have certain conditions. For combination products, warnings often include pre-existing heart disease or high blood pressure, typically due to the inclusion of co-ingredients like decongestants.

How should Parmal be stored and disposed of?

How to Store and Dispose of Parmal (Pyrilamine Maleate)

The official regulatory labeling defines specific conditions for storing and disposing of Parmal to maintain its stability and prevent misuse.

Storage Requirements

Parmal must be stored at controlled room temperature, generally defined as 25 C (77 F), with permitted variations between 15 C and 30 C (59 F and 86 F). The product must be protected from excessive heat and moisture. Liquid forms should not be frozen. All forms must be kept in the original container, which must be tightly closed, and stored out of the reach of children.

Disposal Instructions

Unused or expired Parmal should be disposed of via a drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance (such as used coffee grounds) and sealed in a bag for disposal in the household trash. It is not recommended to dispose of this medicine by flushing it down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Parmal found in:

A-Z Index: